Basel, 04 February 2025- Roche announced today that the US Food and Drug Administration has approved Susvimo ® 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision ...

Basel, 18 July 2024 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for ...

Basel, 22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...

In February 2025, Roche announced that the FDA had approved Susvimo (ranibizumab injection) 100 mg/mL for treating diabetic macular edema (DME), a major cause of vision loss in adults with diabetes.

Roche's Susvimo Gets FDA Green Light for Treatment of Diabetic Retinopathy Provided by Dow Jones May 22, 2025, 4:20:00 PM. By Andrea Figueras .

Roche said that the Food and Drug Administration's decision was based on positive one-year results from the phase III of the Pagoda randomized study, which showed that Susvimo led to sustained ...

Susvimo (ranibizumab injection) was approved in the U.S. in October 2021 to treat wet AMD — a disease which affects the central part of the retina called macula and causes gradual vision loss ...

Roche's (RHHBY) Genentech unit has received FDA approval for its eye drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema. Read more here.

Basel, 22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...

Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight. PR Newswire . Wed, Apr 30, 2025, 5:31 PM 9 min read.